声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。近日，全球领先的合同研究、开发和生产(CRDMO)服务公司药明生物公布2025H1财报，公司实现收益 99.53 亿元，同比增长 16.1%。这一增速不仅高于市场预期，也显示出公司业务发展的良好态势。在利润方面，公司表现更为突出，纯利同比增长54.8%，...
Source Link声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。近日，全球领先的合同研究、开发和生产(CRDMO)服务公司药明生物公布2025H1财报，公司实现收益 99.53 亿元，同比增长 16.1%。这一增速不仅高于市场预期，也显示出公司业务发展的良好态势。在利润方面，公司表现更为突出，纯利同比增长54.8%，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.